American International Group, Inc. Nuvalent, Inc. Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$72.35 - $88.99 $8,103 - $9,966	-112 Reduced 0.85%	13,097 $983,000
Q4 2023 Feb 13, 2024	BUY	$42.42 - $80.28 $52,600 - $99,547	1,240 Added 10.36%	13,209 $972,000
Q3 2023 Nov 13, 2023	BUY	$39.12 - $49.85 $16,626 - $21,186	425 Added 3.68%	11,969 $550,000
Q2 2023 Aug 04, 2023	BUY	$23.58 - $44.68 $43,127 - $81,719	1,829 Added 18.83%	11,544 $486,000
Q1 2023 May 12, 2023	BUY	$25.42 - $33.52 $4,906 - $6,469	193 Added 2.03%	9,715 $253,000
Q4 2022 Feb 10, 2023	BUY	$18.46 - $36.37 $27,486 - $54,154	1,489 Added 18.54%	9,522 $283,000
Q3 2022 Nov 14, 2022	BUY	$13.55 - $19.92 $1,531 - $2,250	113 Added 1.43%	8,033 $156,000
Q2 2022 Aug 12, 2022	SELL	$7.4 - $15.07 $8,717 - $17,752	-1,178 Reduced 12.95%	7,920 $107,000
Q1 2022 May 13, 2022	BUY	$11.65 - $19.57 $39,679 - $66,655	3,406 Added 59.84%	9,098 $126,000
Q4 2021 Feb 11, 2022	SELL	$18.01 - $30.1 $3,061 - $5,117	-170 Reduced 2.9%	5,692 $108,000
Q3 2021 Nov 12, 2021	BUY	$18.25 - $38.35 $106,981 - $224,807	5,862 New	5,862 $132,000

210

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.92B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.